Technology ID
TAB-3488
A Scalable Synthesis of Dual-Target Inhibitor of Cannabinoid-1 Receptor and Inducible Nitric Oxide Synthase
E-Numbers
E-098-2019-0
Lead Inventor
Alimardanov, Asaf
Lead IC
NCATS
Co-Inventors
Huang, Junfeng
ICs
NCATS
Applications
Therapeutics
Therapeutic Areas
Endocrinology
The present invention is directed to a synthesis of a dual-target inhibitor of cannabinoid-1 (CB1R) receptor and inducible nitric oxide synthase, and more specifically, to an improved process for synthesis of (S,1E,NE)-N-(1-aminoethylidene)-3-(4-chlorophenyl)-4-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-4,5-dihydro-1H-pyrazole-1-carboximidamide.
Commercial Applications
This new route and process to synthesis S-MRI1867 without chromatography can be easily adapted to GMP manufacture to produce S-MRI1867 for clinical studies and further commercial production.
Competitive Advantages
This process to produce S-MRI1867 is more time efficient and cost effective. It gives a new version to synthesis the compounds with the core structure similar to S-MRI1867.
Licensing Contact: